Brian Sansoni

We're concerned if the FDA takes maybe a too narrow view regarding the safety and effectiveness data - depending how the final rule ends up - they could take effective products or ingredients off the shelves, they could limit the choice healthcare institutions have.

We're going to try to answer their questions in great detail as called for, but we believe the FDA already has sufficient data on these products.